Clinical Research Directory

Inclusion Criteria: * Adult male or female (≥18 and ≤ 35 years old) * HIV negative at the time of study enrolment (as determined by a rapid blood test for HIV 1,2) * Absence of symptoms of acute HIV infection\* * Body weight ≥ 35 kg * Creatinine clearance ≥ 50 mL/min * Willingness to take PrEP as prescribed and to comply with study procedures. * Willingness to be followed up throughout the duration of the study. Exclusion Criteria: * Confirmed HIV positive by routine antibody testing * Presence of symptoms of acute HIV infection\* * Creatinine clearance (eGFR) of: * Less than 50 mL/min/1.73m2 for adults * For pregnant women: serum creatinine (sCr) greater than 85 µmol/L * Known hypersensitivity to or specific contraindications to the use of TDF or FTC/3TC * Self-reported presence or history of liver cirrhosis (Child-Pugh Class B or greater), with or without viral hepatitis co-infection * Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the participant. This will be an investigator-led determination based on the medical history of the participant. This includes, but is not limited to: • Severe hepatic impairment or history of liver cirrhosis with or without viral hepatitis co-infection. * Participant is judged by the Investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. * Inability or unwillingness to be followed up for the study period * Pregnant and lactating women